

Dieter Niederacher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/589559/publications.pdf>

Version: 2024-02-01

24
papers

2,334
citations

471509

17
h-index

677142

22
g-index

24
all docs

24
docs citations

24
times ranked

5243
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1347.	7.4	390
2	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
3	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	21.4	289
4	RAD51 135Gâ†C Modifies Breast Cancer Risk among <i>BRCA2</i> Mutation Carriers: Results from a Combined Analysis of 19 Studies. <i>American Journal of Human Genetics</i> , 2007, 81, 1186-1200.	6.2	217
5	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Implications for Risk Prediction. <i>Cancer Research</i> , 2010, 70, 9742-9754.	0.9	169
6	Prediction of Breast and Prostate Cancer Risks in Male <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers Using Polygenic Risk Scores. <i>Journal of Clinical Oncology</i> , 2017, 35, 2240-2250.	1.6	152
7	Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. <i>Journal of Clinical Oncology</i> , 2022, 40, 1529-1541.	1.6	90
8	Challenges for CTC-based liquid biopsies: low CTC frequency and diagnostic leukapheresis as a potential solution. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 147-164.	3.1	89
9	Male breast cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: pathology data from the Consortium of Investigators of Modifiers of <i>BRCA1/2</i> . <i>Breast Cancer Research</i> , 2016, 18, 15.	5.0	88
10	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of <i>BRCA1</i> and <i>BRCA2</i> pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	2.4	82
11	<i>BRIP1</i> loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 7.	5.0	78
12	Association Between Loss-of-Function Mutations Within the <i>FANCM</i> Gene and Early-Onset Familial Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 1245.	7.1	74
13	AluY-mediated germline deletion, duplication and somatic stem cell reversion in <i>UBE2T</i> defines a new subtype of Fanconi anemia. <i>Human Molecular Genetics</i> , 2015, 24, 5093-5108.	2.9	62
14	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.9	39
15	A Novel Workflow to Enrich and Isolate Patient-Matched EpCAM ^{high} and EpCAM ^{low/negative} CTCs Enables the Comparative Characterization of the PIK3CA Status in Metastatic Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1885.	4.1	37
16	Frequent allele loss on 9p21â€22 defines a smallest common region in the vicinity of the <i>CDKN2</i> gene in sporadic breast cancer. , 1996, 17, 14-20.		34
17	Resistance to CD95-mediated apoptosis in breast cancer is not due to somatic mutation of the <i>CD95</i> gene. <i>International Journal of Cancer</i> , 2001, 92, 309-310.	5.1	25
18	Breast and Prostate Cancer Risks for Male <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , 2022, 114, 109-122.	6.3	19

#	ARTICLE	IF	CITATIONS
19	EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM. <i>Molecular Cancer Research</i> , 2020, 18, 278-286.	3.4	12
20	Prevalence of Cancer Predisposition Germline Variants in Male Breast Cancer Patients: Results of the German Consortium for Hereditary Breast and Ovarian Cancer. <i>Cancers</i> , 2022, 14, 3292.	3.7	11
21	Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 355-367.	1.5	10
22	Predictors of Impaired Postpartum Renal Function in Women after Preeclampsia: Results of a Prospective Single Center Study. <i>Disease Markers</i> , 2016, 2016, 1-8.	1.3	8
23	The <i>GPRC5A</i> frameshift variant c.183del is not associated with increased breast cancer risk in <i>BRCA1</i> mutation carriers. <i>International Journal of Cancer</i> , 2019, 144, 1761-1763.	5.1	2
24	Implementing microwell slides for detection and isolation of single circulating tumor cells from complex cell suspensions. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2022, 101, 1057-1067.	1.5	1